Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Short-term activity ratio | Description | The company |
---|---|---|
Receivables turnover | An activity ratio equal to revenue divided by receivables. | Humana Inc. receivables turnover ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024. |
Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Humana Inc. payables turnover ratio decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |
Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Humana Inc. working capital turnover ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024. |
Short-term activity ratio | Description | The company |
---|---|---|
Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | |
Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Humana Inc. number of days of payables outstanding increased from Q4 2023 to Q1 2024 but then slightly decreased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |
Receivables Turnover
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
External revenues | 29,242) | 29,323) | 26,168) | 26,115) | 26,473) | 26,549) | 22,279) | 22,627) | 23,615) | 23,967) | 21,088) | 20,730) | 20,469) | 20,590) | 18,848) | 19,361) | 19,006) | 18,786) | 16,145) | 16,105) | 16,131) | 16,006) | |||||||
Receivables, less allowances | 4,090) | 3,925) | 2,035) | 1,824) | 1,429) | 3,107) | 1,674) | 1,609) | 3,369) | 3,174) | 1,814) | 1,879) | 2,438) | 2,196) | 1,138) | 1,135) | 2,238) | 2,009) | 1,056) | 848) | 904) | 1,955) | |||||||
Short-term Activity Ratio | |||||||||||||||||||||||||||||
Receivables turnover1 | 27.10 | 27.54 | 51.75 | 55.60 | 68.53 | 30.60 | 55.25 | 56.74 | 26.54 | 27.18 | 45.69 | 42.91 | 32.51 | 35.43 | 66.78 | 64.58 | 31.30 | 33.43 | 60.97 | — | — | — | |||||||
Benchmarks | |||||||||||||||||||||||||||||
Receivables Turnover, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | 6.64 | 6.61 | 6.58 | 6.13 | 5.40 | 5.70 | 6.12 | 6.06 | 5.88 | — | — | — | |||||||
CVS Health Corp. | 11.17 | 11.16 | 10.12 | 10.53 | 11.44 | 11.65 | 11.79 | 11.94 | 11.27 | 11.30 | 11.91 | 11.23 | 11.48 | 11.32 | 12.32 | 11.14 | 11.68 | 11.33 | 13.04 | — | — | — | |||||||
Elevance Health Inc. | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | 20.66 | 18.93 | 18.81 | 17.39 | 19.72 | 18.91 | 18.04 | 16.74 | 18.20 | — | — | — | |||||||
Intuitive Surgical Inc. | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | 7.30 | 7.90 | 7.38 | 6.96 | 6.75 | 7.32 | 8.56 | 8.73 | 6.94 | — | — | — | |||||||
Medtronic PLC | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | 5.51 | 5.35 | 5.21 | 5.73 | 6.22 | 4.97 | 5.05 | 5.20 | 4.91 | — | — | — | |||||||
UnitedHealth Group Inc. | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | 20.07 | 19.60 | 18.53 | 16.35 | 19.86 | 20.63 | 19.62 | 16.73 | 20.32 | — | — | — |
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q2 2024 Calculation
Receivables turnover
= (External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023
+ External revenuesQ3 2023)
÷ Receivables, less allowances
= (29,242 + 29,323 + 26,168 + 26,115)
÷ 4,090 = 27.10
2 Click competitor name to see calculations.
Short-term activity ratio | Description | The company |
---|---|---|
Receivables turnover | An activity ratio equal to revenue divided by receivables. | Humana Inc. receivables turnover ratio deteriorated from Q4 2023 to Q1 2024 and from Q1 2024 to Q2 2024. |
Payables Turnover
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Benefits | 25,039) | 25,124) | 22,782) | 21,745) | 22,009) | 21,858) | 18,582) | 18,384) | 19,099) | 19,625) | 17,438) | 17,316) | 17,149) | 17,296) | 16,213) | 15,611) | 14,175) | 15,629) | 13,689) | 13,357) | 13,318) | 13,493) | |||||||
Benefits payable | 11,446) | 11,729) | 10,241) | 10,196) | 10,304) | 10,018) | 9,264) | 9,237) | 9,650) | 9,378) | 8,289) | 8,758) | 8,485) | 8,651) | 8,143) | 8,208) | 7,980) | 7,090) | 6,004) | 6,220) | 5,842) | 6,024) | |||||||
Short-term Activity Ratio | |||||||||||||||||||||||||||||
Payables turnover1 | 8.27 | 7.81 | 8.63 | 8.26 | 7.84 | 7.78 | 8.17 | 8.07 | 7.61 | 7.63 | 8.35 | 7.76 | 7.81 | 7.32 | 7.57 | 7.20 | 7.12 | 7.90 | 8.97 | — | — | — | |||||||
Benchmarks | |||||||||||||||||||||||||||||
Payables Turnover, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | 4.21 | 4.55 | 4.43 | 3.97 | 3.80 | 4.37 | 4.00 | 4.20 | 4.07 | — | — | — | |||||||
Cigna Group | 5.63 | 5.92 | 6.75 | 6.76 | 6.92 | 7.18 | 7.31 | 7.44 | 7.44 | 7.89 | 7.68 | 7.71 | 7.60 | 7.74 | 7.75 | 8.02 | 8.30 | 9.06 | 9.34 | — | — | — | |||||||
CVS Health Corp. | 21.49 | 22.40 | 20.36 | 19.73 | 21.32 | 22.08 | 18.07 | 18.75 | 19.22 | 19.38 | 19.14 | 18.49 | 20.72 | 20.50 | 19.72 | 18.61 | 21.70 | 21.06 | 20.13 | — | — | — | |||||||
Elevance Health Inc. | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | 7.59 | 7.31 | 7.30 | 7.31 | 7.75 | 8.32 | 8.42 | 8.48 | 9.25 | — | — | — | |||||||
Intuitive Surgical Inc. | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | 14.45 | 14.13 | 13.71 | 14.80 | 18.35 | 12.46 | 13.18 | 10.69 | 11.08 | — | — | — | |||||||
Medtronic PLC | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | 4.98 | 5.56 | 5.19 | 5.56 | 4.72 | 4.96 | 4.84 | 4.89 | 4.69 | — | — | — | |||||||
UnitedHealth Group Inc. | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | 7.63 | 6.98 | 6.97 | 6.58 | 7.29 | 7.40 | 8.02 | 6.96 | 7.21 | — | — | — |
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q2 2024 Calculation
Payables turnover
= (BenefitsQ2 2024
+ BenefitsQ1 2024
+ BenefitsQ4 2023
+ BenefitsQ3 2023)
÷ Benefits payable
= (25,039 + 25,124 + 22,782 + 21,745)
÷ 11,446 = 8.27
2 Click competitor name to see calculations.
Short-term activity ratio | Description | The company |
---|---|---|
Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Humana Inc. payables turnover ratio decreased from Q4 2023 to Q1 2024 but then increased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |
Working Capital Turnover
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Current assets | 32,858) | 32,796) | 29,986) | 38,253) | 38,759) | 37,532) | 26,183) | 33,711) | 27,217) | 26,840) | 24,893) | 25,815) | 25,790) | 25,526) | 23,641) | 27,031) | 27,868) | 24,551) | 19,888) | 20,324) | 20,160) | 19,673) | |||||||
Less: Current liabilities | 19,790) | 19,689) | 18,872) | 27,823) | 28,279) | 26,942) | 17,178) | 25,051) | 17,839) | 17,532) | 15,331) | 15,027) | 15,051) | 15,300) | 13,394) | 14,905) | 16,455) | 14,830) | 10,929) | 11,106) | 11,539) | 11,927) | |||||||
Working capital | 13,068) | 13,107) | 11,114) | 10,430) | 10,480) | 10,590) | 9,005) | 8,660) | 9,378) | 9,308) | 9,562) | 10,788) | 10,739) | 10,226) | 10,247) | 12,126) | 11,413) | 9,721) | 8,959) | 9,218) | 8,621) | 7,746) | |||||||
External revenues | 29,242) | 29,323) | 26,168) | 26,115) | 26,473) | 26,549) | 22,279) | 22,627) | 23,615) | 23,967) | 21,088) | 20,730) | 20,469) | 20,590) | 18,848) | 19,361) | 19,006) | 18,786) | 16,145) | 16,105) | 16,131) | 16,006) | |||||||
Short-term Activity Ratio | |||||||||||||||||||||||||||||
Working capital turnover1 | 8.48 | 8.25 | 9.47 | 9.72 | 9.34 | 8.98 | 10.27 | 10.54 | 9.53 | 9.27 | 8.67 | 7.47 | 7.38 | 7.61 | 7.42 | 6.04 | 6.14 | 6.91 | 7.19 | — | — | — | |||||||
Benchmarks | |||||||||||||||||||||||||||||
Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | 4.06 | 4.52 | 5.02 | 6.84 | 6.64 | — | — | — | |||||||
Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | 7.23 | 6.79 | 6.67 | 5.38 | 6.39 | 5.98 | 5.40 | 6.81 | 6.11 | — | — | — | |||||||
Intuitive Surgical Inc. | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | 1.22 | 1.17 | 1.03 | 0.88 | 0.77 | 0.80 | 0.88 | 1.23 | 1.23 | — | — | — | |||||||
Medtronic PLC | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | 2.15 | 2.02 | 2.00 | 2.44 | 2.48 | 2.03 | 2.13 | 2.16 | 2.26 | — | — | — | |||||||
UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q2 2024 Calculation
Working capital turnover
= (External revenuesQ2 2024
+ External revenuesQ1 2024
+ External revenuesQ4 2023
+ External revenuesQ3 2023)
÷ Working capital
= (29,242 + 29,323 + 26,168 + 26,115)
÷ 13,068 = 8.48
2 Click competitor name to see calculations.
Short-term activity ratio | Description | The company |
---|---|---|
Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Humana Inc. working capital turnover ratio deteriorated from Q4 2023 to Q1 2024 but then slightly improved from Q1 2024 to Q2 2024. |
Average Receivable Collection Period
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | |||||||||||||||||||||||||||||
Receivables turnover | 27.10 | 27.54 | 51.75 | 55.60 | 68.53 | 30.60 | 55.25 | 56.74 | 26.54 | 27.18 | 45.69 | 42.91 | 32.51 | 35.43 | 66.78 | 64.58 | 31.30 | 33.43 | 60.97 | — | — | — | |||||||
Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||||||
Average receivable collection period1 | 13 | 13 | 7 | 7 | 5 | 12 | 7 | 6 | 14 | 13 | 8 | 9 | 11 | 10 | 5 | 6 | 12 | 11 | 6 | — | — | — | |||||||
Benchmarks (no. days) | |||||||||||||||||||||||||||||
Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | 55 | 55 | 55 | 60 | 68 | 64 | 60 | 60 | 62 | — | — | — | |||||||
CVS Health Corp. | 33 | 33 | 36 | 35 | 32 | 31 | 31 | 31 | 32 | 32 | 31 | 32 | 32 | 32 | 30 | 33 | 31 | 32 | 28 | — | — | — | |||||||
Elevance Health Inc. | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | 18 | 19 | 19 | 21 | 19 | 19 | 20 | 22 | 20 | — | — | — | |||||||
Intuitive Surgical Inc. | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | 50 | 46 | 49 | 52 | 54 | 50 | 43 | 42 | 53 | — | — | — | |||||||
Medtronic PLC | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | 66 | 68 | 70 | 64 | 59 | 73 | 72 | 70 | 74 | — | — | — | |||||||
UnitedHealth Group Inc. | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | 18 | 19 | 20 | 22 | 18 | 18 | 19 | 22 | 18 | — | — | — |
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q2 2024 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 27.10 = 13
2 Click competitor name to see calculations.
Short-term activity ratio | Description | The company |
---|---|---|
Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. |
Average Payables Payment Period
Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | |||||||||||||||||||||||||||||
Payables turnover | 8.27 | 7.81 | 8.63 | 8.26 | 7.84 | 7.78 | 8.17 | 8.07 | 7.61 | 7.63 | 8.35 | 7.76 | 7.81 | 7.32 | 7.57 | 7.20 | 7.12 | 7.90 | 8.97 | — | — | — | |||||||
Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||||||
Average payables payment period1 | 44 | 47 | 42 | 44 | 47 | 47 | 45 | 45 | 48 | 48 | 44 | 47 | 47 | 50 | 48 | 51 | 51 | 46 | 41 | — | — | — | |||||||
Benchmarks (no. days) | |||||||||||||||||||||||||||||
Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||||||
Abbott Laboratories | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | 87 | 80 | 82 | 92 | 96 | 83 | 91 | 87 | 90 | — | — | — | |||||||
Cigna Group | 65 | 62 | 54 | 54 | 53 | 51 | 50 | 49 | 49 | 46 | 48 | 47 | 48 | 47 | 47 | 46 | 44 | 40 | 39 | — | — | — | |||||||
CVS Health Corp. | 17 | 16 | 18 | 19 | 17 | 17 | 20 | 19 | 19 | 19 | 19 | 20 | 18 | 18 | 19 | 20 | 17 | 17 | 18 | — | — | — | |||||||
Elevance Health Inc. | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | 48 | 50 | 50 | 50 | 47 | 44 | 43 | 43 | 39 | — | — | — | |||||||
Intuitive Surgical Inc. | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | 25 | 26 | 27 | 25 | 20 | 29 | 28 | 34 | 33 | — | — | — | |||||||
Medtronic PLC | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | 73 | 66 | 70 | 66 | 77 | 74 | 75 | 75 | 78 | — | — | — | |||||||
UnitedHealth Group Inc. | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | 48 | 52 | 52 | 56 | 50 | 49 | 46 | 52 | 51 | — | — | — |
Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q2 2024 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 8.27 = 44
2 Click competitor name to see calculations.
Short-term activity ratio | Description | The company |
---|---|---|
Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Humana Inc. number of days of payables outstanding increased from Q4 2023 to Q1 2024 but then slightly decreased from Q1 2024 to Q2 2024 not reaching Q4 2023 level. |